The news of JMP Securities analyst David Turkaly reiterating a Market Perform rating on Globus Medical (NYSE:GMED) is directly related to the company. However, since the rating is a reiteration and not an upgrade or downgrade, the short-term impact on the stock price is expected to be neutral.